News and Publications
June 10, 2020
Coriell Life Sciences’ Return to Operations Program as Featured on 6abc Action News Philadelphia
“With more businesses opening up and more people heading back into the office, there are new concerns. But there’s some help for that.” CLS’ Scott Megill discussed our new COVID-19 Return to Operations program for organizations and schools with 6abc Action News.
With Coriell Life Sciences, you get the power in knowing exactly when it’s time to return and how to keep your organization running safely.
May 21, 2020
First-of-its-Kind ‘COVID-19 Risk Score’ Launches to Enable Safer Re-opening and Return to Work Plans
Coriell Life Sciences’ advanced data analytics examine individuals’ health history to identify those who are more likely to have severe or fatal outcomes if infected with novel coronavirus.
As more businesses and employees prepare to return to work around the country, Coriell Life Sciences (CLS) is rolling out a new tool in the fight against COVID-19: personalized COVID-19 Risk Scores. Using proprietary, advanced data analytics, CLS analyzes information from medical records to identify the number of unique risk factors linked to poor COVID-19 outcomes an individual has. Factors include thousands of potential risk elevators, from cardiovascular disease, diabetes and hypertension to allergies, anemia, and more. The higher the number of risk factors, the higher the likelihood of experiencing severe or fatal symptoms if infected with the virus.
COVID-19 risk scoring is part of CLS’ new Return to Work Program. This program provides an intelligence-driven solution designed to help organizations safely resume operations. In addition to analyzing employee and facility data to illuminate risks and barriers to re-opening, the program offers businesses turnkey infrastructure for managing large-scale COVID-19 testing of employees in partnership with a network of laboratories across the country.
May 8, 2020
Greater Philadelphia’s Health Care & Life Sciences Organizations Contribute to Coronavirus Response
Coriell Life Sciences provides ready-made path for laboratories
Coriell Life Sciences in Philadelphia, a bioinformatics company and leading provider of molecular test interpretation and reporting, is offering its coronavirus analysis and reporting services to laboratories throughout the U.S. at no cost during this period of public health crisis. “To speed our national response to stemming the spread of the COVID-19 virus, we feel we can contribute by creating a ready-made path for laboratories ramping up access to this testing.” said Scott Megill, President and CEO of Coriell Life Sciences.
March 12, 2020
Coriell Life Sciences to Provide Coronavirus COVID-19 Reporting to Laboratories
Coriell Life Sciences responds to public health crisis by providing key service at no cost
Coriell Life Sciences (CLS), a leading provider of molecular test interpretation and reporting, is offering its coronavirus analysis and reporting services to laboratories throughout the United States at no cost during this period of public health crisis.
“Laboratory testing is not as simple as running a sample through a machine. The results must be interpreted and developed into a clinical report that laboratories either need to design and build, or they can partner with providers like Coriell Life Sciences. To speed our national response to stemming the spread of the COVID-19 virus, we feel we can contribute by creating a ready-made path for laboratories ramping up access to this testing.” said Scott Megill, President and CEO of Coriell Life Sciences.
March 4, 2020
Personalized Medicine Conference spotlights Coriell Life Sciences’ medication risk management program
Coriell Life Sciences was proud to accept the Excellence Award in the Cost Containment category at the Pharmacy Benefit Management Institute’s (PBMI) 25th Annual National Conference in Orlando, FL.
Coriell Life Sciences brings a depth of scientific expertise spanning six decades. CLS’ President and CEO, Scott Megill, explains, “We demonstrate a unique ability to execute commercially and can ensure success for state-run retirement systems like TRS-KY and responsible companies in charge of employee and member health and well-being. We have crafted our model to address what is right for the patient and the payer. CLS’s network of laboratories, software tools, and customer-focused resources stand at the ready.”
November 15, 2019
Personalized Medicine Conference spotlights Coriell Life Sciences’ medication risk management program
At the annual Personalized Medicine Conference in Boston held November 13-14, Coriell Life Sciences President and CEO Scott Megill joined Jane Cheshire Gilbert, director of retiree healthcare for the Teachers’ Retirement System (TRS) Kentucky to discuss implementing a medication risk management program among the TRS Kentucky pension fund’s 36,000 Medicare-eligible retirees. Administered by Coriell Life Sciences, this comprehensive program driven by genetic testing helped the pension fund to dramatically improve retirees’ health, reduce adverse drug reactions, and lower overall costs.
November 2, 2019
Program implementation and evaluation data translates into medication safety and big savings
Join Coriell Life Sciences at APHA 2019, the annual meeting and expo of the American Public Health Association, where the company will present its latest precision public health findings at the Genomics Forum on November 5 at 10:30 a.m. The APHA Annual Meeting, one of the nation’s most influential public health events, will be held November 2-6 in Philadelphia, PA.
November 1, 2019
Coriell Life Sciences has expanded its leadership team and announced three new roles. Chief Financial Officer William Testa, CPA, started on June 17; Chief Revenue Officer Jennifer Ferrang, MBA, joined the company on September 30; and Director of Precision Medicine Aissa Aifaoui, PharmD, Clinical Pathologist, began on October 15.
September 27, 2019
Molecular Diagnosis Delivers Fast, Highly Accurate Vaginitis Testing
Novel diagnostic tools offer women more effective treatment and healing
If you’re a woman who has had vaginitis, you know that getting a fast, accurate diagnosis is the key to effective treatment and relief. Vaginitis is one of the most common and frustrating health concerns for millions of women around the world—and yet, the diagnosis of vaginitis has historically relied on the use of clinical assessment supported by outdated and often inaccurate microscopic methods.
August 27, 2019
KPMG, Coriell Life Sciences And Thermo Fisher Scientific To Collaborate On Links Between Medications And Genes
- Heightened capability aimed at improving pharmacy safety, health outcomes with the use of genetic testing
- Leading life sciences company with expertise in genetic analysis instruments and consumables coupled with pharmacogenomics and medication safety management company’s capabilities available to KPMG’s Care Continuum Optimization clients
KPMG’s Clinical Intelligence (KCI) platform is helping clinicians improve the quality of care by furnishing them with pharmacogenomics data – information about how genes interact with medicines – from Coriell Life Sciences (CLS), supported by Thermo Fisher Scientific’s leading genetic analysis platform and content.
July 31, 2019
Advancing Actionable Clinical Support for Mental Health Providers
- Coriell Life Sciences explores the consequences of patient-specific changes in the key gene CYP2D6 in psychiatry
- Findings intended to assist frontline providers with better understanding of the ways genetic variation can help guide therapy
Novel technologies like pharmacogenomic (PGx) analysis look at the genes that control a patient’s ability to metabolize many commonly used drugs, and offer important insight into patient physiology which can have a significant impact in psychiatric care and treatment outcomes.
May 20, 2018
Coriell Life Sciences Teams with Quantigen Genomics to Transform Women’s Health
New molecular women’s health report provides complete decision support for the detection of vaginal infections
Coriell Life Sciences (CLS), an innovative provider of clinical genetic reporting solutions, today announced the launch of their next-generation solution for the quantitative diagnosis and reporting of bacterial vaginosis (BV). The test can simultaneously aid in the differential diagnosis of other vaginal infections that clinically present with the same signs and symptoms as BV.
May 1, 2018
Coriell Life Sciences Pilot Partner Wins 2018 SALGBA Challenge Award
Teachers’ Retirement System of Kentucky personalized medicine pilot receives national recognition
Coriell Life Science is excited to share that Teachers’ Retirement System of Kentucky Personalized Medicine Project received a national award for health care innovation from the State and Local Government Benefits Association (SALGBA). Members of the TRS insurance team were on hand to accept the SALGBA Innovation Challenge Award at its annual national conference on May 1st, 2018.